Home › Funds › Palo Alto Investors LP › BMRN
Palo Alto Investors LP position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
Palo Alto Investors LP reported holding 642,455 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$38.5M, representing 5.73% of its reported portfolio and ranking #5 among its reported holdings. Palo Alto Investors LP has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's BMRN position evolved
Palo Alto Investors LP first disclosed a stake in BMRN in Q3 2023 at 1,831,035 shares (US$162.0M). Across 13 filings, Palo Alto Investors LP increased the stake 0 time(s), trimmed it 10 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 642,455 shares valued at US$38.5M — a reduction of -40,322 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.83M | $162.01M | New |
| Q4 2023 | 1.50M | $144.70M | Reduce |
| Q1 2024 | 1.13M | $99.09M | Reduce |
| Q2 2024 | 1.13M | $93.05M | Hold |
| Q3 2024 | 1.09M | $76.62M | Reduce |
| Q4 2024 | 1.07M | $70.15M | Reduce |
| Q1 2025 | 991.21K | $70.07M | Reduce |
| Q2 2025 | 840.47K | $46.20M | Reduce |
| Q3 2025 | 754.01K | $40.84M | Reduce |
| Q4 2025 | 746.26K | $44.35M | Reduce |
| Q1 2026 | 685.18K | $38.71M | Reduce |
| Q2 2026 | 682.78K | $39.07M | Hold |
| Q3 2026 | 642.46K | $38.55M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$899.3M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$430.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.99M sh · $899.34M · Q3 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.17M sh · $430.39M · Q3 2026
- Deep Track Capital, LP 6.37M sh · $382.46M · Q3 2026
- Vestal Point Capital, LP 5.53M sh · $331.50M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 2.03M sh · $121.51M · Q3 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $109.58M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held BMRN?
Palo Alto Investors LP has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Palo Alto Investors LP's current position in BMRN?
As of Q3 2026, Palo Alto Investors LP holds 642.46K shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $38.55M, representing 5.73% of its reported portfolio and ranking #5.
Has Palo Alto Investors LP been buying or selling BMRN?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in BMRN.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.